StockNews.AI
KURA
StockNews.AI
181 days

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

1. Kura plans Q4 2024 results release on February 26, 2025. 2. Ziftomenib has FDA Breakthrough Therapy Designation for AML treatment. 3. Global collaboration with Kyowa Kirin for ziftomenib's development established. 4. Continued trials for ziftomenib in AML and other hematologic cancers. 5. Phase 1 trials ongoing for next-gen therapies KO-2806 and Tipifarnib.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming results could signal progress and heightened investor interest.

How important is it?

Kura's financial results and collaborations could significantly impact investor perceptions.

Why Short Term?

The results announcement will likely influence immediate trading activity.

Related Companies

KURAKYKUF
February 19, 2025 07:30 ET  | Source: Kura Oncology, Inc. SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (the “FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) 513-1284patti.bank@icrhealthcare.com Media:Alexandra WeingartenAssociate Director, Corporate Communications & Investor Relations(858) 500-8822alexandra@kuraoncology.com

Related News